{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor-positive+Human+Epidermal+Growth+Factor+2-negative&page=2", "query": { "condition": "Hormone Receptor-positive Human Epidermal Growth Factor 2-negative", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor-positive+Human+Epidermal+Growth+Factor+2-negative&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T12:23:20.581Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06139107", "title": "RADIANT: Pre-op Radiation With Abemaciclib and Letrozole", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mridula George, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "FEMALE", "summary": "60 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2024-08-22", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 4, "location_summary": "Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Somerville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06139107" }, { "nct_id": "NCT06465368", "title": "A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07220060", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 121, "start_date": "2024-07-11", "completion_date": "2025-07-10", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 10, "location_summary": "Barrington, Illinois • Crystal Lake, Illinois • Park Ridge, Illinois + 2 more", "locations": [ { "city": "Barrington", "state": "Illinois" }, { "city": "Crystal Lake", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06465368" }, { "nct_id": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Epithelial Ovarian Cancer", "High Grade Serous Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Non-small Cell Lung Cancer", "Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)", "Mesothelioma", "Breast Adenocarcinoma", "Triple Negative Breast Cancer", "Hormone Receptor-positive/Her2 Negative Breast Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Platinum Sensitive Ovarian Cancer (PSOC)", "Primary Refractory Ovarian Cancer", "Uterine Cancer" ], "interventions": [ { "name": "Rina-S", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 884, "start_date": "2022-12-07", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579366" }, { "nct_id": "NCT03219476", "title": "Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Invasive Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2017-02-05", "completion_date": "2025-03-20", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219476" }, { "nct_id": "NCT04895358", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" }, { "name": "dextrose", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2021-06-18", "completion_date": "2027-12-18", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Monterey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895358" }, { "nct_id": "NCT07310420", "title": "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "ZOLADEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TerSera Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 88, "start_date": "2026-06-30", "completion_date": "2027-03-30", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 11, "location_summary": "Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 8 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Lisle", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07310420" }, { "nct_id": "NCT04305496", "title": "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced (Inoperable) or Metastatic Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 818, "start_date": "2020-04-16", "completion_date": "2026-06-22", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 22, "location_summary": "Gilbert, Arizona • Orange, California • San Francisco, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04305496" }, { "nct_id": "NCT06586957", "title": "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor", "Solid Tumor, Adult", "Metastatic Tumor", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Metastatic Ovarian Carcinoma", "Endometrial Neoplasms", "Endometrial Diseases", "Metastatic Endometrial Cancer", "Triple Negative Breast Cancer", "Metastatic Endometrial Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Ovarian Carcinoma", "Gastric Cancer", "Advanced Gastric Carcinoma", "Metastatic Gastric Cancer", "Metastatic Gastric Carcinoma", "Small Cell Lung Cancer", "Small Cell Lung Carcinoma", "Triple Negative Breast Neoplasms", "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Carcinoma", "CCNE1 Amplification", "Hormone Receptor Negative Breast Carcinoma", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Progesterone-receptor-positive Breast Cancer" ], "interventions": [ { "name": "NKT3964", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-09-19", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06586957" }, { "nct_id": "NCT06966700", "title": "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Triple Negative Breast Neoplasms", "HR Low-Positive/HER2-Negative Breast Neoplasms" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2400, "start_date": "2025-06-30", "completion_date": "2034-12-29", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 53, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 46 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06966700" }, { "nct_id": "NCT04460911", "title": "Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2019-10-19", "completion_date": "2022-04-01", "has_results": true, "last_update_posted_date": "2024-01-11", "last_synced_at": "2026-06-10T12:23:20.581Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460911" } ] }